ALT5 Sigma CorpALTS決算レポート
Nasdaq · 金融 · 商品取引仲介業者及び取引商
ALT5 Sigma Corp is a fintech firm focused on digital asset infrastructure and trading solutions. It operates regulated digital asset trading platforms for retail and institutional clients, primarily serving markets across North America, Europe, and the Asia-Pacific region. Its core offerings include spot and derivatives trading, digital asset custody, and secure settlement services.
What changed in ALT5 Sigma Corp's 10-K — 2021 vs 2022
Top changes in ALT5 Sigma Corp's 2022 10-K
4 paragraphs added · 4 removed · 4 edited across 2 sections
- Item 1. Business+3 / −3 · 3 edited
- Item 1A. Risk Factors+1 / −1 · 1 edited
Item 1. Business
Business — how the company describes what it does
3 edited+0 added−0 removed408 unchanged
Item 1. Business
Business — how the company describes what it does
3 edited+0 added−0 removed408 unchanged
2021 filing
2022 filing
In connection with that determination, we determined that we would not then file a utility patent nor submit an investigational new drug application to the FDA. This determination was based on several factors, including the current, positive effect that three vaccines are having on the COVID-19 pandemic in the United States.
In connection with that determination, we determined that we would not then file a utility patent nor submit an investigational new drug application to the FDA. This determination was based on several factors, including the current, positive effect that three vaccines are having on the COVID-19 pandemic in the United States.
It is estimated that chronic pain affects 100 million individuals in the United States and over 1.5 billion people worldwide; thus, more people suffer from chronic pain than diabetes, heart disease, and cancer combined (Cowen Therapeutic Categories Outlook, March 2019).
It is estimated that chronic pain affects 100 million individuals in the United States and over 1.5 billion people worldwide; thus, more people suffer from chronic pain than diabetes, heart disease, and cancer combined (Cowen Therapeutic Categories Outlook, March 2019).
Chronic pain exacts a tremendous cost in terms of direct treatment and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden for patients and their families.
Chronic pain exacts a tremendous cost in terms of direct treatment and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden for patients and their families.
Item 1A. Risk Factors
Risk Factors — what could go wrong, per management
1 edited+0 added−0 removed217 unchanged
Item 1A. Risk Factors
Risk Factors — what could go wrong, per management
1 edited+0 added−0 removed217 unchanged
2021 filing
2022 filing
Even though our patents provide protection for specific uses, we will not be able to prevent other companies from developing the same API for other uses.
Even though our patents provide protection for specific uses, we will not be able to prevent other companies from developing the same API for other uses.